Medicare unveils 2027 rates for private Medicare, Part D plans
CMS said most Medicare Advantage enrollees will keep the same or lower premiums, while some Part D plans may trim drug coverage.
- On Tuesday, CMS announced average 2027 Medicare Advantage premiums will fall to $12 from $14.37 in 2026, while stand-alone Part D premiums will rise to $36.
- The Part D increase follows the end of a Biden-era "demonstration project" that cost $9.8 billion in 2025 and 2026; CMS said the program is returning to normal market conditions.
- Market stability remains high, with 97% of Medicare enrollees having access to 10 or more Medicare Advantage plan options for 2027, and total available plans holding steady at 5,532.
- Juliette Cubanski, vice president and director of the program on Medicare policy for KFF, said insurers are "bending over backward to try and keep premiums as low as possible," though plans may trim drug formularies to offset costs.
- Medicare open enrollment runs from Oct. 15 through Dec. 7 for coverage beginning Jan. 1, 2027. John Brooks, director of Medicare at CMS, urged enrollees to assess whether their current plans still meet their needs.
19 Articles
19 Articles
Medicare updated the premiums for 2027 with promotions that will leave a category at US$36, while 88% of beneficiaries will have basic plans.
Average Medicare Advantage Premiums to Decline by 16 Percent in 2027, Federal Department Projects
At the same time, the number of Medicare Advantage choices will drop in 28 states and Washington, and monthly premiums will go up in 19 states in 2027.
Medicare Advantage premiums expected to drop more than 16% in 2027, CMS projects - Regional Media News
Sept 29 (Reuters) - The Centers for Medicare & Medicaid Services estimates the weighted average premium for Medicare Advantage (MA) plans to fall more than 16% next year. The weighted average monthly premium across all MA plans, which include MA prescription drug plans and special [...]
Trump CMS faces bipartisan pushback over Medicare proposal tied to Biden
EXCLUSIVE: A bipartisan group of more than 50 lawmakers is urging the Trump administration not to finalize a proposed Medicare policy tied to the Biden-era drug price negotiation program, arguing it could discourage development of improved cancer treatments. In a Sept. 21 letter obtained by Fox News Digital, the lawmakers called on Centers for Medicare … The post Trump CMS faces bipartisan pushback over Medicare proposal tied to Biden appeared f…
Coverage Details
Bias Distribution
- 69% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium

















